Syngeneic tumor models
are important preclinical research tools for immuno-oncology drug discovery. One challenge that researchers may encounter when studying novel therapeutics in syngeneic tumor models is immunogenicity. Biologics can induce an immune response in the host, including the development of anti-drug antibodies (ADA). ADA can prevent determination of efficacy of a biologic drug. One solution to this problem is to perform the syngeneic tumor study in a mouse strain that lacks B cells. The Jh mouse
lacks B cells but retains other immune cell types. For biologic drugs which are immunogenic in wild type mice, the Jh mouse provides a system in which to evaluate efficacy without the interference of anti-drug antibodies. The Jh mouse cannot produce anti-drug antibodies which change the half-life or neutralize the therapeutic. It can accommodate repeat dosing without risk of antibody-mediated anaphylaxis.
Download the infographic
or watch the video below to learn more: